AT9258U2 - Transdermal-pflaster zum verabreichen von fentanyl - Google Patents

Transdermal-pflaster zum verabreichen von fentanyl Download PDF

Info

Publication number
AT9258U2
AT9258U2 AT0013207U AT1322007U AT9258U2 AT 9258 U2 AT9258 U2 AT 9258U2 AT 0013207 U AT0013207 U AT 0013207U AT 1322007 U AT1322007 U AT 1322007U AT 9258 U2 AT9258 U2 AT 9258U2
Authority
AT
Austria
Prior art keywords
fentanyl
administration
transdermal plaster
transdermal
plaster
Prior art date
Application number
AT0013207U
Other languages
English (en)
Other versions
AT9258U3 (de
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23058257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT9258(U2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AT9258U2 publication Critical patent/AT9258U2/de
Publication of AT9258U3 publication Critical patent/AT9258U3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Ein Verfahren und ein nicht in seiner Abgaberate gesteuertes monolithisches, untersättigtes Pflaster zur transdermalen Verabreichung von Fentanyl und Analogstoffen desselben zu analgetischen Zwecken an eine Person durch die Haut über einen ausgedehnten Zeitraum.
AT0013207U 2001-03-16 2007-03-02 Transdermal-pflaster zum verabreichen von fentanyl AT9258U3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27683701P 2001-03-16 2001-03-16

Publications (2)

Publication Number Publication Date
AT9258U2 true AT9258U2 (de) 2007-07-15
AT9258U3 AT9258U3 (de) 2008-05-15

Family

ID=23058257

Family Applications (4)

Application Number Title Priority Date Filing Date
AT02715112T ATE364380T1 (de) 2001-03-16 2002-03-15 Transdermales pflaster zur verabreichung von fentanyl
AT0031105U AT8273U1 (de) 2001-03-16 2005-05-10 Transdermal-pflaster zum verabreichen von fentanyl
AT0034606U AT8585U3 (de) 2001-03-16 2006-04-26 Transdermal-pflaster zum verabreichen von fentanyl
AT0013207U AT9258U3 (de) 2001-03-16 2007-03-02 Transdermal-pflaster zum verabreichen von fentanyl

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT02715112T ATE364380T1 (de) 2001-03-16 2002-03-15 Transdermales pflaster zur verabreichung von fentanyl
AT0031105U AT8273U1 (de) 2001-03-16 2005-05-10 Transdermal-pflaster zum verabreichen von fentanyl
AT0034606U AT8585U3 (de) 2001-03-16 2006-04-26 Transdermal-pflaster zum verabreichen von fentanyl

Country Status (21)

Country Link
US (11) US20030026829A1 (de)
EP (1) EP1381352B1 (de)
JP (7) JP5354763B2 (de)
KR (1) KR100904158B1 (de)
CN (2) CN101524339A (de)
AT (4) ATE364380T1 (de)
CA (1) CA2440884C (de)
CY (1) CY1106834T1 (de)
CZ (1) CZ307857B6 (de)
DE (3) DE20221841U1 (de)
DK (2) DK1381352T3 (de)
ES (1) ES2270746T3 (de)
FI (2) FI6962U1 (de)
IL (3) IL157822A0 (de)
MX (1) MXPA03008349A (de)
NZ (1) NZ528148A (de)
PL (1) PL363079A1 (de)
PT (1) PT1381352E (de)
RU (2) RU2708563C2 (de)
WO (1) WO2002074286A1 (de)
ZA (1) ZA200308026B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE20221841U1 (de) * 2001-03-16 2008-05-21 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
CN101406703A (zh) 2002-04-23 2009-04-15 阿尔扎公司 降低了滥用可能的经皮止痛系统
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE10223835A1 (de) * 2002-05-28 2003-12-11 Labtec Gmbh Pflaster, enthaltend Fentanylum
WO2003101433A1 (de) * 2002-05-28 2003-12-11 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend fentanylum
EP1386604A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales Verabreichungssystem
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
AU2004210406B2 (en) * 2003-02-07 2008-10-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
EP2319505A1 (de) * 2003-04-30 2011-05-11 Purdue Pharma L.P. Transdermale dosierungsformen, die eine wirkstoffkomponente und eine entgegengesetzt wirksame komponente in einem verhältnis von 1:10 bis 10:1 enthalten
KR20060120678A (ko) 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
PT1530967E (pt) 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US20080262445A1 (en) * 2004-09-08 2008-10-23 Dermatrends, Inc. Transdermal Delivery of Hydrophobic Bioactive Agents
NZ582975A (en) * 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
US8252320B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
AU2012201164B2 (en) * 2004-10-21 2014-07-24 Durect Corporation Transdermal delivery systems
GB0509276D0 (en) * 2005-05-06 2005-06-15 Univ Cranfield Synthetic receptor
PT1895994E (pt) * 2005-05-13 2010-12-03 Alza Corp Sistema de administração de medicamentos de camada múltipla com barreira contra o fluxo de material do reservatório
TWI419717B (zh) * 2005-06-17 2013-12-21 Altea Therapeutics Corp 滲透傳送系統及其使用方法
WO2007011987A2 (en) * 2005-07-18 2007-01-25 Alza Corporation Device and method for increasing the throughput of irritation testing of transdermal formulations
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
EP1948142B1 (de) * 2005-09-23 2014-04-09 ALZA Corporation Polyacrylatformulierung mit hoher beladung von verstärkenden substanzen für transdermale anwendungen
US20070202156A1 (en) * 2006-02-13 2007-08-30 Aveva Drug Deliverty Systems Adhesive preparation comprising sufentanil and methods of using same
CA2646206A1 (en) * 2006-04-21 2007-11-01 Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh Transdermal delivery system comprising sufentanil and its analogues
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
US20080004671A1 (en) * 2006-06-28 2008-01-03 Alza Corporation Vagus nerve stimulation via orally delivered apparatus
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
FR2912643B1 (fr) * 2007-02-15 2009-04-17 Dbv Technologies Sa Patch pour application cutanee
JP5192722B2 (ja) * 2007-04-27 2013-05-08 祐徳薬品工業株式会社 外用貼付剤
WO2009005814A2 (en) * 2007-07-03 2009-01-08 Marchitto Kevin S Drug-delivery patch comprising a dissolvable layer and uses thereof
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
KR101583680B1 (ko) * 2007-10-15 2016-01-08 알자 코퍼레이션 펜타닐의 1일-1회 교체 경피 투여
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
KR101829920B1 (ko) 2008-01-28 2018-02-19 데이고꾸세이약꾸가부시끼가이샤 펜타닐 함유 외용 패치
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
PT2712622T (pt) 2008-05-21 2016-10-13 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono tranquilo
CN101780057B (zh) * 2009-01-21 2012-09-05 考司美德制药株式会社 经皮吸收贴剂
NZ596398A (en) 2009-07-24 2013-08-30 Teikoku Seiyaku Kk Fentanyl-containing adhesive preparation for external use
EP2295046B1 (de) 2009-09-14 2012-12-19 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
KR101955175B1 (ko) 2010-04-13 2019-03-06 나지브 바불 1-메틸-2'-6'-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
EP2462927A1 (de) 2010-12-03 2012-06-13 Hexal AG Transdermales therapeutisches System mit Fentanyl
KR20120107153A (ko) * 2011-03-15 2012-10-02 아이큐어 주식회사 펜타닐 경피 패치제
US20140243765A1 (en) * 2011-09-22 2014-08-28 Samyang Biopharmaceuticals Corporation Percutaneously absorbable preparation containing fentanyl and homologue thereof
EP2599478A1 (de) 2011-11-30 2013-06-05 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
WO2016009063A1 (en) 2014-07-18 2016-01-21 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
BR112017003248B1 (pt) 2014-08-25 2022-10-11 Henkel IP & Holding GmbH Composição compreendendo copolímero acrílico
JP6940407B2 (ja) * 2014-12-19 2021-09-29 キンデーバ ドラッグ デリバリー リミティド パートナーシップ フェンタニルを含む経皮薬物送達デバイス
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
EP3067050A1 (de) 2015-03-13 2016-09-14 Acino AG Transdermales therapeutisches system mit einem overtape mit zwei haftschichten
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
EP3556359A4 (de) 2016-12-19 2020-08-05 Nutritape, S.L. Energetisierungspflaster für sportler
CN110536861B (zh) 2017-04-18 2023-07-04 突破技术有限责任公司 硫的生产
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
RU2712918C1 (ru) * 2019-08-01 2020-02-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера
CN110693857B (zh) * 2019-10-17 2023-08-11 宜昌人福药业有限责任公司 一种舒芬太尼透皮贴剂及其制备方法
US11229611B2 (en) 2020-04-30 2022-01-25 Taho Pharmaceuticals Ltd. Clobazam transdermal delivery system and uses thereof
RU204475U1 (ru) * 2020-09-24 2021-05-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт медицины труда имени академика Н.Ф. Измерова" (ФГБНУ "НИИ МТ") Медицинский аппликатор для местного лечения кожных заболеваний
US11369789B2 (en) 2021-04-05 2022-06-28 Ishaan Jain Transdermal drug delivery system

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352708A (en) * 1964-03-02 1967-11-14 Ball Brothers Co Inc Glass having dual protective coatings thereon and method for forming such coatings
US3886126A (en) * 1973-04-09 1975-05-27 Monsanto Co Solutions of pressure-sensitive resin solutions with improved viscosity and flow
US3900610A (en) * 1973-04-09 1975-08-19 Monsanto Co Process of making a pressure sensitive adhesive article
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS57142258A (en) * 1981-02-27 1982-09-02 Nitto Electric Ind Co Drug containing tape preparation
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4954343A (en) * 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
JPH0818975B2 (ja) * 1987-06-08 1996-02-28 日東電工株式会社 疾患治療用貼付剤
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5364630A (en) * 1988-06-14 1994-11-15 Alza Corporation Subsaturated nicotine transdermal therapeutic system
WO1991003219A1 (en) * 1989-09-08 1991-03-21 Cygnus Research Corporation Solid matrix system for transdermal drug delivery
JP3046346B2 (ja) * 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
RU2056865C1 (ru) * 1992-02-25 1996-03-27 Новокузнецкий филиал Института общей реаниматологии РАМН Способ лечения печеночной недостаточности у больных с эндо- и экзогенными токсикозами
DE4310012A1 (de) 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
AU679793B2 (en) * 1993-09-29 1997-07-10 Alza Corporation Monoglyceride/lactate ester permeation enhancer
JP4102901B2 (ja) 1994-09-14 2008-06-18 スリーエム カンパニー 経皮薬剤導入用マトリックス
US5714162A (en) * 1994-09-16 1998-02-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Scopolamine patch
KR100188180B1 (ko) * 1994-12-24 1999-06-01 서경배 경피투여용 패취제제
US6154190A (en) * 1995-02-17 2000-11-28 Kent State University Dynamic drive methods and apparatus for a bistable liquid crystal display
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US6093419A (en) * 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
DE19527925C2 (de) * 1995-07-29 1997-07-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht
US5900198A (en) * 1996-01-31 1999-05-04 Hori; Yasunori Method of producing molded resin product
JP3836566B2 (ja) * 1996-05-13 2006-10-25 久光製薬株式会社 フェンタニル含有経皮投与テープ製剤
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
EP0934078B1 (de) * 1996-10-24 2002-12-18 Alza Corporation Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
AU1728099A (en) * 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
KR19980025307A (ko) * 1998-04-11 1998-07-06 조태임 진통효과를 갖는 약물의 경피흡수제제
CA2331264C (en) * 1999-01-14 2008-09-23 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
JP4643018B2 (ja) * 1999-04-13 2011-03-02 久光製薬株式会社 経皮吸収型製剤
IT1312198B1 (it) * 1999-04-21 2002-04-09 De Nora Spa Cella a combustibile raffreddata mediante iniezione diretta di acqualiquida
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
KR20010036685A (ko) * 1999-10-11 2001-05-07 김윤 펜타닐을 함유하는 매트릭스형 경피투여제
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6455066B1 (en) * 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE20221841U1 (de) * 2001-03-16 2008-05-21 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20040001882A1 (en) * 2002-03-06 2004-01-01 Hexal Ag Transdermal system with fentanyl
CN101406703A (zh) * 2002-04-23 2009-04-15 阿尔扎公司 降低了滥用可能的经皮止痛系统
TWI296531B (en) * 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
DE10252725A1 (de) * 2002-11-13 2004-06-03 Lts Lohmann Therapie-Systeme Ag Feuchtigkeitsaktivierbare Klebstoffe für medizinische Anwendungszwecke
KR20060120678A (ko) * 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
JP4745747B2 (ja) * 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery

Also Published As

Publication number Publication date
CN101524339A (zh) 2009-09-09
HK1068545A1 (zh) 2005-04-29
PT1381352E (pt) 2007-07-27
US20140030316A1 (en) 2014-01-30
DE60220661D1 (de) 2007-07-26
WO2002074286A1 (en) 2002-09-26
EP1381352A1 (de) 2004-01-21
CY1106834T1 (el) 2012-05-23
FIU20050202U0 (fi) 2005-06-02
CZ307857B6 (cs) 2019-07-03
RU2708563C2 (ru) 2019-12-10
ATE364380T1 (de) 2007-07-15
DK200500030U3 (da) 2005-07-22
RU2007113373A (ru) 2008-10-27
FI6962U1 (fi) 2006-02-13
FI7341U1 (fi) 2006-12-27
JP2004524336A (ja) 2004-08-12
JP6437971B2 (ja) 2018-12-12
JP2011037884A (ja) 2011-02-24
EP1381352B1 (de) 2007-06-13
US20140271799A1 (en) 2014-09-18
CN100508974C (zh) 2009-07-08
DK1381352T3 (da) 2007-07-09
US20210113541A1 (en) 2021-04-22
US20160331740A1 (en) 2016-11-17
IL157822A0 (en) 2004-03-28
AT8273U1 (de) 2006-05-15
US20180098979A1 (en) 2018-04-12
CZ20032813A3 (cs) 2004-08-18
NZ528148A (en) 2006-02-24
JP2014224145A (ja) 2014-12-04
AT9258U3 (de) 2008-05-15
RU2351318C2 (ru) 2009-04-10
US20190167655A1 (en) 2019-06-06
RU2003127841A (ru) 2005-03-27
US20030026829A1 (en) 2003-02-06
ZA200308026B (en) 2004-10-15
AU2002247331C1 (en) 2002-10-03
JP2017014268A (ja) 2017-01-19
DK200500030Y4 (da) 2006-07-28
CA2440884A1 (en) 2002-09-26
PL363079A1 (en) 2004-11-15
ES2270746T3 (es) 2007-12-01
KR100904158B1 (ko) 2009-06-23
IL157822A (en) 2016-05-31
AT8585U2 (de) 2006-10-15
ES2270746T1 (es) 2007-04-16
KR20030082995A (ko) 2003-10-23
CA2440884C (en) 2012-05-22
JP5354763B2 (ja) 2013-11-27
JP2018109021A (ja) 2018-07-12
US20200054619A1 (en) 2020-02-20
US20040213832A1 (en) 2004-10-28
US20090004257A1 (en) 2009-01-01
IL243302A0 (en) 2016-02-29
DE20221841U1 (de) 2008-05-21
FIU20060295U0 (fi) 2006-07-11
DE60220661T2 (de) 2008-02-14
JP2012197302A (ja) 2012-10-18
CN1535142A (zh) 2004-10-06
US20200289488A1 (en) 2020-09-17
JP5950704B2 (ja) 2016-07-13
AT8585U3 (de) 2007-02-15
JP2020023541A (ja) 2020-02-13
DK200500030U1 (da) 2005-05-13
DE02715112T1 (de) 2007-04-19
MXPA03008349A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
AT9258U2 (de) Transdermal-pflaster zum verabreichen von fentanyl
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
DE602004017720D1 (de) Bausatz, vorrichtung und verfahren zur gesteuerten abgabe eines oxidationsmittels in die haut
DK1476141T3 (da) Manipulationssikrede anordninger til transdermal opioidadministration
DK1530469T3 (da) Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE60213976D1 (de) Vorrichtung zur manipulation von nadeln oder polierarray
ATE439123T1 (de) Verwendung von emulsionen zur intra- und periocularen injection
DE60037218D1 (de) Pflaster und Verfahren zur transdermalen Verabreichung von Bupropion als freie base
DE60204229D1 (de) Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
EP1518580A3 (de) Vorrichtung zur Bestimmung des Sedierungsniveaus eines Patienten
DE60111494D1 (de) Verfahren zur erhöhung der wachsamkeit durch verabreichung von vomeropherin und vomeropherin emittierende alarmvorricthung
NO20071636L (no) Flytende allergivaksineformulering for oromukosal administrering
DE10342071A1 (de) Vorrichtung und Verfahren zur Applikation von WIrkstoffen an eine Wundoberfläche
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
EP1767183A4 (de) Verfahren zur wiederherstellung von haaren, verfahren zur fixierung und stabilisierung eines haarmittels und bei den verfahren verwendetes haarwiederherstellungs-setzmittel
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
EP1691779A4 (de) Behandlung eines zustands in einem säugetier mit verabreichung von verbindungen und anwendungsverfahren dafür
DE502004002706D1 (de) Darreichungsform zur oralen verabreichung von wirkstoffen, vitaminen und/oder nährstoffen, kit und verwendung
EP1875898A3 (de) Transdermales Pflaster zur Verabreichung von Fentanyl
DE60028207D1 (de) Transdermales therapeutisches system zur verabreichung von calciumantagonisten
EP1339253A3 (de) Tragbares Kommunikationsgerät und Verfahren zum Betreiben desselben

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20120331

MN9K Cancelled due to lapse of time